Literature DB >> 23219372

The predictive value of C-reactive protein for prognosis in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy: a multi-institutional study.

Nobuyuki Tanaka1, Eiji Kikuchi, Suguru Shirotake, Kent Kanao, Kazuhiro Matsumoto, Hiroaki Kobayashi, Yasumasa Miyazaki, Hiroki Ide, Jun Obata, Katsura Hoshino, Nozomi Hayakawa, Yujiro Ito, Takeo Kosaka, Kiichiro Kodaira, Masafumi Oyama, Akira Miyajima, Tetsuo Momma, Ken Nakagawa, Munehisa Ueno, Mototsugu Oya.   

Abstract

BACKGROUND: Few studies have discussed the prognostic impact of serum C-reactive protein (CRP) level in upper tract urothelial carcinoma (UTUC).
OBJECTIVE: To investigate whether the perioperative level of CRP provides additional prognostic information following radical nephroureterectomy (RNU). DESIGN, SETTING, AND PARTICIPANTS: A total of 564 patients with UTUC from a retrospective multi-institutional cohort were included. The median follow-up was 32 mo. INTERVENTION: All patients underwent RNU without neoadjuvant chemotherapy, while 106 patients (18.8%) received adjuvant chemotherapy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Associations between perioperative CRP level and outcome were assessed using multivariate analysis. A serum CRP level >0.50mg/dl was defined as elevated. RESULTS AND LIMITATIONS: Preoperative CRP (pre-CRP) level was elevated in 136 patients (24.1%). Multivariate analysis showed that pre-CRP elevation was an independent predictor of subsequent disease recurrence (hazard ratio [HR]: 1.47 for CRP 0.51-2.00; HR: 1.89 for CRP >2.00). Five-year recurrence-free survival rates were 69.2% in patients with pre-CRP levels ≤ 0.50 mg/dl, 54.3% in patients with pre-CRP levels between 0.51 and 2.00 mg/dl, and 35.4% in patients with pre-CRP levels >2.00 mg/dl (p<0.001). Similar results were found in cancer-specific mortality, showing that pre-CRP elevation was an independent predictor of worse outcome (HR: 1.74 for CRP 0.51-2.00; HR: 2.31 for CRP >2.00). In a subgroup analysis of the elevated pre-CRP group, postoperative normalisation of CRP level was an independent predictor of better outcome. This study is limited by its retrospective nature as well as its heterogeneous group of patients and variable follow-up protocols resulting from the multi-institution design.
CONCLUSIONS: Serum CRP may become a possible biomarker in UTUC, suggesting that patients with an elevated pre-CRP level could be predicted to have subsequent disease recurrence and cancer-specific mortality, while postoperative normalisation of CRP level was an independent predictor for prognosis.
Copyright © 2012 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  C-reactive protein; Outcome; Survival; Upper urinary tract; Urothelial carcinoma

Mesh:

Substances:

Year:  2012        PMID: 23219372     DOI: 10.1016/j.eururo.2012.11.050

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  26 in total

1.  Preoperative C-reactive protein as a prognostic predictor for upper tract urothelial carcinoma: A systematic review and meta-analysis.

Authors:  You Luo; Sheng Jun Fu; Dong Li She; H U Xiong; L I Yang
Journal:  Mol Clin Oncol       Date:  2015-04-24

2.  Impact of preoperative hemoglobin and CRP levels on cancer-specific survival in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder: results of a single-center study.

Authors:  T Grimm; A Buchner; B Schneevoigt; A Kretschmer; M Apfelbeck; M Grabbert; J F Jokisch; C G Stief; A Karl
Journal:  World J Urol       Date:  2015-09-16       Impact factor: 4.226

3.  Impaction of ureteral stones into the ureteral wall: Is it possible to predict?

Authors:  Kemal Sarica; Bilal Eryildirim; Cahit Sahin; Kubilay Sabuncu; Cihangir Cetinel; Fehmi Narter
Journal:  Urolithiasis       Date:  2015-12-11       Impact factor: 3.436

4.  Preoperative risk factors for extraurothelial recurrence in N0M0 patients with renal pelvic cancer treated by radical nephroureterectomy.

Authors:  Keiichi Ito; Junichi Asakuma; Kenji Kuroda; Kazuyoshi Tachi; Akinori Sato; Akio Horiguchi; Kenji Seguchi; Tomohiko Asano
Journal:  Mol Clin Oncol       Date:  2016-01-28

5.  Impact of C-reactive Protein Flare Response in Patients With Advanced Urothelial Carcinoma Who Received Pembrolizumab.

Authors:  Ikko Tomisaki; Mirii Harada; Kei Tokutsu; Akinori Minato; Yujiro Nagata; Rieko Kimuro; Masahiro Matsumoto; Naohiro Fujimoto
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.155

6.  Preoperative Underweight Patients with Upper Tract Urothelial Carcinoma Survive Less after Radical Nephroureterectomy.

Authors:  Ho Won Kang; Hae Do Jung; Yun-Sok Ha; Tae-Hwan Kim; Tae Gyun Kwon; Seok-Soo Byun; Seok-Joong Yun; Wun-Jae Kim; Young Deuk Choi
Journal:  J Korean Med Sci       Date:  2015-09-12       Impact factor: 2.153

7.  High expression of KPNA2 defines poor prognosis in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy.

Authors:  Bentao Shi; Boxing Su; Dong Fang; Yuan Tang; Gengyan Xiong; Zhongqiang Guo; Qun He; Xinyu Yang; Wei Zhao; Yinglu Guo; Xuesong Li; Liqun Zhou
Journal:  BMC Cancer       Date:  2015-05-09       Impact factor: 4.430

8.  Prognostic Role of C-Reactive Protein In Urological Cancers: A Meta-Analysis.

Authors:  Liang Zhou; Xiang Cai; Qiang Liu; Zhong-Yu Jian; Hong Li; Kun-Jie Wang
Journal:  Sci Rep       Date:  2015-08-03       Impact factor: 4.379

9.  Validation of the pretreatment derived neutrophil-lymphocyte ratio as a prognostic factor in a European cohort of patients with upper tract urothelial carcinoma.

Authors:  O Dalpiaz; M Pichler; S Mannweiler; J M Martín Hernández; T Stojakovic; K Pummer; R Zigeuner; G C Hutterer
Journal:  Br J Cancer       Date:  2014-04-01       Impact factor: 7.640

Review 10.  Pretreatment Neutrophil to Lymphocyte Ratio as a Prognostic Predictor of Urologic Tumors: A Systematic Review and Meta-Analysis.

Authors:  You Luo; Dong-Li She; Hu Xiong; Sheng-Jun Fu; Li Yang
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.